EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy

Stephen M Brown iD, Aparna S Ajjarapu, Divya Ramachandra, Laura Blasco-Pérez, Mar Costa-Roger, Eduardo F Tizzano, Charlotte J Sumner, Katherine D Mathews

Annals of Clinical and Translational Neurology · 2024-11 · 11 (11) · 3042-3046

DOI: 10.1002/acn3.52213 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.09.2024. Verfasst von Stephen M Brown und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Infant, Premature, Muscular Atrophy, Spinal, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke of the National Institutes of Health, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Twin girls born at 30 weeks' gestation with spinal muscular atrophy (SMA) received onsasemnogene‐abeparvovec (OA) at 3.5 weeks of life. They had no treatment‐related adverse events, normal acquisition of motor milestones, and normal neurological examination at 19 months. Genotyping revealed 0 copies of SMN1 and a single, hybrid SMN2 gene containing the positive genetic modifier c.835‐44A>G. This was associated with full‐length SMN2 blood mRNA expression levels similar to a 2 copy SMA infant. The observed favorable outcomes are likely due to the genetic modifier combined with early drug administration enabled by prematurity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infant, PrematureMuscular Atrophy, SpinalSurvival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 ProteinFemaleHumansInfantInfant, NewbornBiological ProductsDiseases in TwinsRecombinant Fusion Proteins

Substanzen

Biological ProductsSurvival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 ProteinSMN1 protein, humanSMN2 protein, humanZolgensmaRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
  • Department of Genetics, Advocate Children's Hospital, Oak Lawn, Illinois, USA.
  • Department of Clinical and Molecular Genetics and Medicine Genetics Group, VHIR, Hospital Vall d'Hebron, Barcelona, Spain.
  • Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

ORCID-Profile: Stephen M Brown

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke of the National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Brown, S. M., Ajjarapu, A. S., Ramachandra, D., Blasco-Pérez, L., Costa-Roger, M., Tizzano, E. F., Sumner, C. J., & Mathews, K. D. (2024). Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy. Annals of Clinical and Translational Neurology, 11(11), 3042-3046. https://doi.org/10.1002/acn3.52213

Vancouver

Brown SM, Ajjarapu AS, Ramachandra D, Blasco-Pérez L, Costa-Roger M, Tizzano EF, et al. Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy. Annals of Clinical and Translational Neurology. 2024;11(11):3042-3046. doi:10.1002/acn3.52213

BibTeX
@article{Brown2024,
  author = {Brown, Stephen M and Ajjarapu, Aparna S and Ramachandra, Divya and Blasco-Pérez, Laura and Costa-Roger, Mar and Tizzano, Eduardo F and Sumner, Charlotte J and Mathews, Katherine D},
  title = {Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {11},
  pages = {3042--3046},
  doi = {10.1002/acn3.52213}
}
Kostenlos starten →